Lyell Immunopharma Reports $3K Revenue and $1.86 Loss Per Share
For 2026, Lyell reported a $45.53 million net loss, compared with $38.85 million in 2025. Revenue was $3,000 versus $15,000, while diluted loss per share was $1.86 versus $2.13.
Lyell Immunopharma reported revenue of $3K and a net loss of $45.53M for 2026, compared with revenue of $15K and a net loss of $38.85M in 2025. Diluted loss per share was $1.86, versus $2.13 in the prior-year period.Financial Highlights¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported a…